No clinically meaningful adverse changes from baseline and no meaningful differences between treatment groups were observed in neutrophil counts, although both dupilumab + TCS groups showed a trend to decrease in mean neutrophil counts from baseline to Week 16 (Fig. 1 d; Supplemental Table S3a, see ESM).
← all excerpts
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
1
—
—